Literature DB >> 20797489

Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry.

Adam S Fein1, Yongfei Wang, Jeptha P Curtis, Frederick A Masoudi, Paul D Varosy, Matthew R Reynolds.   

Abstract

OBJECTIVES: The purpose of the study was to define the extent and nature of cardiac resynchronization therapy (CRT) device usage outside consensus guidelines using national data.
BACKGROUND: Recent literature has shown that the application of CRT in clinical practice frequently does not adhere to evidence-based consensus guidelines. Factors underlying these practices have not been fully explored.
METHODS: From the National Cardiovascular Data Registry's Implantable Cardiac-Defibrillator Registry, we defined a cohort of 45,392 cardiac resynchronization therapy-defibrillator (CRT-D) implants between January 2006 and June 2008 with a primary prevention indication. We defined "off-label" implants as those in which the ejection fraction was >35%, the New York Heart Association functional class was below III, or the QRS interval duration was <120 ms in the absence of a documented need for ventricular pacing. The relationships between patient, implanting physician, and hospital characteristics with off-label use were explored with multivariable hierarchical logistic regression models.
RESULTS: Overall, 23.7% of devices were placed without meeting all 3 implant criteria, most often due to New York Heart Association functional class below III (13.1% of implants) or QRS interval duration <120 ms (12.0%). Atrial fibrillation/flutter, previous percutaneous coronary intervention, and the performance of an electrophysiology study before implant were independently associated with increased odds of off-label use, whereas diabetes mellitus, increasing age, and female sex were associated with decreased odds. Physician training and insurance payer were weakly associated with the likelihood of off-label use.
CONCLUSIONS: Nearly 1 in 4 patients receiving CRT devices in the study time frame did not meet guideline-based indications. Given the evolving evidence base supporting the use of CRT, these practices require careful scrutiny. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20797489      PMCID: PMC2958057          DOI: 10.1016/j.jacc.2010.05.025

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  29 in total

1.  Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database.

Authors:  Douglas S Lee; Andrew D Krahn; Jeffrey S Healey; David Birnie; Eugene Crystal; Paul Dorian; Christopher S Simpson; Yaariv Khaykin; Douglas Cameron; Amir Janmohamed; Raymond Yee; Peter C Austin; Zhongliang Chen; Judy Hardy; Jack V Tu
Journal:  J Am Coll Cardiol       Date:  2010-02-23       Impact factor: 24.094

2.  Temporal trends in the utilization of diagnostic testing and treatments for cardiovascular disease in the United States, 1993-2001.

Authors:  F L Lucas; Michael A DeLorenzo; Andrea E Siewers; David E Wennberg
Journal:  Circulation       Date:  2006-01-24       Impact factor: 29.690

3.  2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.

Authors:  Mariell Jessup; William T Abraham; Donald E Casey; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Marvin A Konstam; Donna M Mancini; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2009-03-26       Impact factor: 29.690

4.  Underutilization of beta-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures.

Authors:  Paul J Hauptman; Jason P Swindle; Frederick A Masoudi; Thomas E Burroughs
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-03-02

5.  Results of the Predictors of Response to CRT (PROSPECT) trial.

Authors:  Eugene S Chung; Angel R Leon; Luigi Tavazzi; Jing-Ping Sun; Petros Nihoyannopoulos; John Merlino; William T Abraham; Stefano Ghio; Christophe Leclercq; Jeroen J Bax; Cheuk-Man Yu; John Gorcsan; Martin St John Sutton; Johan De Sutter; Jaime Murillo
Journal:  Circulation       Date:  2008-05-05       Impact factor: 29.690

6.  Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator.

Authors:  Jeptha P Curtis; Jeffrey J Luebbert; Yongfei Wang; Saif S Rathore; Jersey Chen; Paul A Heidenreich; Stephen C Hammill; Rachel I Lampert; Harlan M Krumholz
Journal:  JAMA       Date:  2009-04-22       Impact factor: 56.272

7.  Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure.

Authors:  Martin St John Sutton; Stefano Ghio; Ted Plappert; Luigi Tavazzi; Laura Scelsi; Claude Daubert; William T Abraham; Michael R Gold; Christian Hassager; John M Herre; Cecilia Linde
Journal:  Circulation       Date:  2009-10-26       Impact factor: 29.690

8.  Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.

Authors:  Claude Daubert; Michael R Gold; William T Abraham; Stefano Ghio; Christian Hassager; Grahame Goode; Tamás Szili-Török; Cecilia Linde
Journal:  J Am Coll Cardiol       Date:  2009-10-01       Impact factor: 24.094

9.  Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005.

Authors:  Sana M Al-Khatib; Melissa A Greiner; Eric D Peterson; Adrian F Hernandez; Kevin A Schulman; Lesley H Curtis
Journal:  Circ Arrhythm Electrophysiol       Date:  2008-10

10.  Cardiac-resynchronization therapy for the prevention of heart-failure events.

Authors:  Arthur J Moss; W Jackson Hall; David S Cannom; Helmut Klein; Mary W Brown; James P Daubert; N A Mark Estes; Elyse Foster; Henry Greenberg; Steven L Higgins; Marc A Pfeffer; Scott D Solomon; David Wilber; Wojciech Zareba
Journal:  N Engl J Med       Date:  2009-09-01       Impact factor: 91.245

View more
  13 in total

1.  Increasing knowledge and changing views in cardiac resynchronization therapy.

Authors:  Laszlo Buga; John G F Cleland
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

2.  Nonpharmacological Treatment of Atrial Fibrillation: What Is the Role of Device Therapy?

Authors:  Lucie Riedlbauchová; Václav Durdil; Jakub Honěk; Josef Veselka
Journal:  Int J Angiol       Date:  2020-04-28

3.  Medical device postapproval safety monitoring: where does the United States stand?

Authors:  Prashant V Rajan; Daniel B Kramer; Aaron S Kesselheim
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-01-06

Review 4.  Cardiac Resynchronization Therapy in Patients with Atrial Fibrillation - Worth the Effort?

Authors:  António M Ferreira; Pedro Carmo; Pedro Adragão
Journal:  J Atr Fibrillation       Date:  2012-04-14

5.  Prevalence of guideline-directed medical therapy among patients receiving cardiac resynchronization therapy defibrillator implantation in the National Cardiovascular Data Registry during the years 2006 to 2008.

Authors:  Preston M Schneider; Cara N Pellegrini; Yongfei Wang; Adam S Fein; Matthew R Reynolds; Jeptha P Curtis; Frederick A Masoudi; Paul D Varosy
Journal:  Am J Cardiol       Date:  2014-04-01       Impact factor: 2.778

6.  Expanding indications for resynchronization therapy.

Authors:  Christophe Leclercq; Nathalie Behar; Philippe Mabo; Jean-Claude Daubert
Journal:  Curr Cardiol Rep       Date:  2012-10       Impact factor: 2.931

7.  Temporal trends in quality of care among recipients of implantable cardioverter-defibrillators: insights from the National Cardiovascular Data Registry.

Authors:  John A Dodson; Rachel Lampert; Yongfei Wang; Stephen C Hammill; Paul Varosy; Jeptha P Curtis
Journal:  Circulation       Date:  2013-11-05       Impact factor: 29.690

8.  Evaluation of the Charlson comorbidity index to predict early mortality in implantable cardioverter defibrillator patients.

Authors:  Sanjeev P Bhavnani; Craig I Coleman; Danette Guertin; Ravi K Yarlagadda; Christopher A Clyne; Jeffrey Kluger
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05-03       Impact factor: 1.468

9.  Mortality risk following replacement implantable cardioverter-defibrillator implantation at end of battery life: results from the NCDR.

Authors:  Daniel B Kramer; Kevin F Kennedy; John A Spertus; Sharon-Lise Normand; Peter A Noseworthy; Alfred E Buxton; Mark E Josephson; Peter J Zimetbaum; Susan L Mitchell; Matthew R Reynolds
Journal:  Heart Rhythm       Date:  2014-02       Impact factor: 6.343

10.  Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR.

Authors:  Daniel B Kramer; Kevin F Kennedy; Peter A Noseworthy; Alfred E Buxton; Mark E Josephson; Sharon-Lise Normand; John A Spertus; Peter J Zimetbaum; Matthew R Reynolds; Susan L Mitchell
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.